It's always a bit of a let-down when we're back from all of the excitement at ASN. We found the sessions thought-provoking and the discussions with nephrologists and other clinicians invigorating. We got to share Renalytix news, which included receiving FDA De Novo Marketing authorization for kidneyintelX.dkd and our still relatively new consortium partnership in Prime CKD, where together, we are striving to shape the future of precision medicine in CKD. Here's a pic of some of the Prime CKD crew, from left to right: Peter Rossing, Hiddo Jan L. Heerspink, Wenjun Ju, Sharon Stapleton (Renalytix), Viji Nair, Fergus Fleming (Renalytix), Michael J. Donovan PhD, MD (Renalytix), and Matthias Kretzler.
I am extremely proud to be a part of PRIME-CKD!
President of Sales at Métier Medical Limited
11moI look forward to the significant move forward in the share price as the past 24 month have been extremely difficult.